key: cord-0913891-afgckqns
authors: Malhi, Navraj; Moghaddam, Nima; Hosseini, Farshad; Singer, Joel; Lee, Terry; Turgeon, Ricky D.; Wong, Graham C.; Fordyce, Christopher B.
title: Care and Outcomes of ST-Segment–Elevation Myocardial Infarction across multiple Coronavirus Disease 2019 (COVID-19) waves
date: 2022-02-10
journal: Can J Cardiol
DOI: 10.1016/j.cjca.2022.01.033
sha: ee77722b1890b73b13d543520e644fab35af67f0
doc_id: 913891
cord_uid: afgckqns

BACKGROUND: There are concerns of delays in ST-segment elevation myocardial infarction (STEMI) care during the coronavirus 2019 (COVID-19) pandemic. It is unclear whether the care and outcomes of STEMI patients differ between COVID-19 waves compared to historical periods. METHODS: Consecutive patients in the Vancouver Coastal Health Authority (VCHA) STEMI database were included to compare care during 3 distinct waves of the COVID-19 pandemic (9 months; March 2020 to January 2021) with a historical non-COVID-19 cohort. We compared STEMI incidence, baseline characteristics and outcomes between groups. We also examined time from first medical contact (FMC)-to-reperfusion, symptom-to-FMC and FMC-to-STEMI diagnosis, as well as predictors of delays. RESULTS: The incidence of STEMI was similar during COVID-19 (n=305; mean 0.93/day) and pre-COVID-19 (n=949; 0.97/day p=0.80). The COVID-19 cohort showed significant delay in FMC-to-reperfusion (median:116 mins vs. 102 mins, p<0.001) and FMC-to-STEMI diagnosis (median: 17 mins vs. 11 mins, p<0.001). Delays in FMC-to-device times worsened across the first three COVID-19 waves (FMC-to-device time ≤90 minutes in wave 1: 32.9%, wave: 2: 25.6%, wave 3: 16.3%; P=0.045 (47.5% pre-COVID-19; P<0.001). There were no significant predictors of delay were unique to the COVID-19 cohort. CONCLUSIONS: This study demonstrates delays in reperfusion during the COVID-19 pandemic compared to the historical control, with delays during subsequent waves within the pandemic. It is critical to further understand these care gaps to improve STEMI care for future waves of the current and future pandemics.

Timely pharmacologic or mechanical reperfusion of the infarct-related artery remains the cornerstone of treatment for ST segment elevation myocardial infarction (STEMI) 1 ; delayed reperfusion is associated with increased morbidity and mortality. 2 The global COVID-19 pandemic has placed considerable strain on health care systems, both in terms of physician resources and access to specialized care and in this manner has impacted upon the timely treatment of non-COVID-19 conditions STEMI. 3

Significant regional variability also exists on the impact of the COVID-19 pandemic on the management of STEMI patients. While patients in COVID-19 epicenters may be more reluctant to present to the hospital, resulting in potential delays in seeking acute cardiac care, this may not be the case in other regions less impacted by the COVID-19 pandemic. For example, data emerging from mainland China, Northern Italy, and Spain revealed a significant delay in seeking first medical contact after symptom onset. [4] [5] [6] [7] This, however, was not the case in less impacted regions such as Germany or Belgium. 8, 9 Similar regional variability of in-hospital mortality was found in a recent systematic review looking at STEMI outcomes during the COVID-19 pandemic. 10 Despite these regional differences, consistent and significant delay in door-to-device times were seen during the COVID-19 pandemic. 10 These delays have been thought to be related to the need for stringent infection control measures adopted by local hospitals, and extensive testing and preparation measures required for STEMI patients with suspected COVID-19 infection. However, no study to date has reported how outcomes in STEMI have differed over the subsequent, multiple waves of infections with the COVID-19.

This analysis aimed to evaluate the regional impact of the COVID-19 outbreak on STEMI care and patient outcomes in the Vancouver Coastal Health Authority (VCHA) during multiple COVID-19 waves with 4 specific objectives. The first objective was to compare the incidence of STEMI cases during the COVID-19 outbreak with incidence prior to the pandemic, as well as to assess trends in the incidence of STEMI cases between three distinct waves of the pandemic. The second objective was to determine the difference in baseline clinical characteristics between patients presenting with STEMI during the COVID-19 outbreak compared to prior to the pandemic. The third objective was to compare care and outcomes of STEMI patients during and prior to the COVID-19 pandemic as exploratory outcomes, as well as during the three waves of the pandemic. The fourth objective was to determine predictors of delay in care in STEMI patients presenting during the COVID-19 pandemic and pre-pandemic period.

In this study, we included all patients with STEMI referred to the VCHA during the COVID-19 outbreak for a period from March 11 th 2020 until January 31, 2021. This included all patients who were medically managed, or who underwent reperfusion with fibrinolysis or primary PCI (pPCI), which is defined as a strategy of taking patients with STEMI directly for percutaneous coronary intervention. Patients with STEMI complicated with out-of-hospital cardiac arrest were also included. To serve as a historical comparator group, all patients with STEMI in the VCHA regional STEMI registry from March 11 th until January 31 st in 2017, 2018 and 2019 were included as controls.

J o u r n a l P r e -p r o o f

All data was collected and analyzed at the Centre for Health Evaluation and Outcomes Sciences (CHEOS), using the VCHA STEMI database. In existence since 2007, this database (n = 4400 patients) provides continuous and ongoing collection of detailed pre-and in-hospital information on consecutive STEMI patients presenting to VCHA hospitals (12 hospitals serving 25% of the British Columbia (BC) population, urban and rural), for stakeholder reporting and quality improvement as previously described. [11] [12] [13] For the current study, STEMI patients were stratified into whether they presented during the COVID-19 pandemic (March 11 th , 2020 to January 31 st , 2021) vs. during a non-COVID-19 time period (March 11 th to January 31 st 2017, 2018, and 2019)( Figure 1 ). For secondary analyses, patients presenting during the COVID-19 pandemic were sub-classified into three distinct waves corresponding with three consecutive 109 day intervals into the following dates: wave 1 (March 11th to June 27th 2020), wave 2 (June 28th to October 14th 2020) and wave 3 (October 15th 2020 to January 31st 2021). All data was collected by the VCHA STEMI database study coordinators by retrospective chart review using a standard data collection form.

The co-primary outcomes were STEMI incidence and time from first medical contact (FMC)-toreperfusion during COVID-19 compared with pre-COVID-19 cohorts. Our secondary outcomes included times from symptom-to-FMC and FMC-to-STEMI diagnosis. We examined in-hospital clinical outcomes as exploratory analyses. These included all-cause mortality, major bleeding J o u r n a l P r e -p r o o f events, congestive heart failure, cardiogenic shock, in-hospital cardiac arrest, left ventricular ejection fraction (LVEF) post STEMI, and length of hospital stay.

Lastly, we identified predictors for timely pPCI (FMC-to-device ≤90 minutes for direct presenters, ≤120 minutes for transfers) in patients presenting with STEMI during and prior to the COVID-19 pandemic.

All data were analyzed with Statistical Analysis System (SAS) software version 9.2 (SAS institute, Cary, NC). Continuous variables were measured as medians with interquartile range or means ±SDs, and categorical variables were measured as percentages. Comparisons between the COVID-19 and Pre-COVID-19 cohorts were performed using the Kruskal-Wallis test or ANOVA for continuous variables and the X 2 or Fisher exact test for categorical variables as appropriate. STEMI related time intervals were compared between the three waves in the same fashion. We further used quantile regression with natural cubic spline to examine how the median of the STEMI related time intervals changed during the COVID-19 period. To avoid overfitting the data, the number of knots for the cubic spline was chosen based on goodness of fit of the model as assessed by Akaike information criterion and a maximum of 5 knots was used due to limited sample size. Proportion of patients with delayed pPCI during the COVID-19 period was similarly analyzed using spline logistic regression. Univariate logistic regression analyses were done to determine the associations of clinically important patient-and systemlevel variables with FMC-to-device time ≤90 minutes (or ≤120 minutes for transfers) in the COVID-19 and pre-COVID-19 cohorts. Variables with p<0.1 in the univariate analysis were J o u r n a l P r e -p r o o f included in a multivariable logistic regression model for further assessment. Statistical significance was determined as a P value of < 0.05.

The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written. This project was conducted in compliance with the protocol and principles laid down in the Declaration of Helsinki, along with other local regulatory requirements. Before the study initiation, written approval from the University of British Columbia Ethics Review Board was obtained (H05-50241).

There were 1254 patients who met the inclusion criteria, including 305 (25.4%) during the COVID-19 pandemic and 949 during the same time period from 2017-2019. Most participants were male (80%) and mean age was 65.6 years ( Figure 1 ). The COVID-19 and Pre-COVID-19 groups were similar in baseline cardiac risk factors, medical comorbidities and previous revascularization ( Table 1) . Sixty-five percent of patients in both cohorts presented to PCIcapable centers. There was no statistical difference in STEMI incidence during COVID-19 Similarly, there was no significant difference in pre-hospital cardiac arrest or cardiogenic shock on presentation (9.2% vs 9.9%, 95% CI [-4.5, 3.4]; P=0.71). There was a significantly higher incidence of heart failure on presentation in the COVID-19 group compared to pre-COVID-19 (12.2% vs. 5.3%, 95% CI [2.9, 11.3]; P<0.001).

There was no difference between groups from symptom onset to seeking medical attention, as they had a median symptom-to-FMC interval of 64 (IQR 28, 180) minutes compared to 63 (IQR 28, 170) minutes in the pre-COVID-19 group (P = 0.685). There was a statistically significant delay in first medical contact to STEMI diagnosis in the COVID-19 group compared to the pre- (Table 2) .

FMC-to-device, symptom-to-FMC, and FMC-to-STEMI diagnosis times did not differ between COVID-19 waves (Table 3) . However, the proportion of patients with FMC-to-device time ≤90 minutes (or ≤120 minutes when presenting at a non PCI center) decreased across subsequent period in a continuous fashion during the study period, there was significant increase in FMCdevice time (p=0.037) as the pandemic progressed, with the highest delay being in the third COVID-19 wave ( Figure 5 ). This was also accompanied by a trend to increased FMC-STEMI interval in wave 3 but this did not reach statistical significance (p=0.053). There was not a statistically significant change in symptom-FMC time.

Exploratory in-hospital clinical outcomes were analyzed and are displayed in Table 4 . There was J o u r n a l P r e -p r o o f no difference in mortality from STEMI between the Pre-COVID-19 and COVID-19 groups.

Similarly, there was no difference in in-hospital cardiac arrest, re-infarction or developing cardiogenic shock, LVEF, or length of hospital stay. Fewer patients experienced a major bleeding events in the COVID-19 group (OR 0.67; 95% CI [0.45, 0.99]; P=0.04).

Finally, when examining predictors of delay in FMC-to-device time in the COVID-19 cohort, several predictors were found (Table 5) ; however, there were no significant differences between the COVID-19 and pre-COVID-19 cohorts in terms of the association between delay in FMC-todevice time and potential predictors (all p for homogeneity of OR>0.05). Increasing age (OR Similarly, STEMI presentation outside of daytime hours predicted delayed FMC-to-device time, with the strongest association seen with presentation between 00:00 to 07:59 (OR 2.52; 95% CI [1.14 to 5.57]; P=0.023). In particular, there were no unique predictors of delay in FMC-todevice time in the COVID-19 cohort, that were not also present in the pre-COVID-19 cohort.

Our findings remained the same in the multivariable analysis (Supplementary Table S4 ).

In the current study, there was a significant delay in STEMI care in patients presenting during the COVID-19 pandemic compared to the same timeframe in the 3 years preceding COVID-19.

Furthermore, there was a significant increase in time from FMC-to-STEMI diagnosis and FMCto-reperfusion time. These findings point to delays in in-hospital processes related STEMI care J o u r n a l P r e -p r o o f which are supported by a large systematic review and meta-analysis by Rattka et al. 10 Similar findings have been previously reported in observational studies around the world, 4, 8, 9, [14] [15] [16] [17] [18] [19] including a recently published Canadian study by Clifford et al, who described STEMI care in an Ontario population during the COVID-19 pandemic. 14 Our results were discrepant with previously reported studies as we did not find that there was a significant reduction in patients presenting with STEMI during the COVID-19 pandemic.

Average STEMI numbers per day were 0.93 during the COVID-19 pandemic vs. 0.97 in the historical control group (p = 0.80). The Rattka systematic review, for example, found that there was a 22% reduction in patients presenting with STEMI during the COVID-19 pandemic compared to prior. 10 Similarly, there was a 16% reduction in coronary angiography for STEMI seen across Canada in a national study published by Rinfret et al during a three month COVID-19 period compared to a historical control. 20 However, in this study, there was no statistical difference seen in British Columbia, which is concordant with our results.

Canada can perhaps be explained by lower rates of COVID-19 cases in British Columbia compared to other areas around the world during this timeframe. According to statistics provided by the British Columbia Center for Disease Control (BCCDC), COVID-19 cases were relatively low (consistently less than 200 cases per day) for the first several months of the pandemic, before surging to 800 cases per day in November and December 2020. 21 As British Columbia had a relatively delayed 'spike' in COVID-19 numbers, it is possible that patients did not have as much perceived fear of presenting to hospital as patients in other countries heavily impacted J o u r n a l P r e -p r o o f earlier on during the pandemic. [21] [22] [23] This may also represent a concerted effort by public health officials and physicians in British Columbia in raising education around cardiovascular disease and the importance of seeking help despite concerns over the pandemic. This lack of fear of presenting to healthcare during the COVID-19 pandemic is further supported by our finding of no difference between symptom-to-FMC interval between the COVID-19 and pre-COVID-19

cohorts.

As far as we are aware, we are the first to report 'inter-wave' data on STEMI care during the COVID-19 pandemic. To evaluate STEMI care within the different waves of the pandemic, we divided the COVID-19 pandemic into three consecutive 109 day intervals. Surprisingly, we found that as the COVID-19 pandemic progressed, there was a statistically significant increased number of patients that did not meet the goal FMC-to-device time. There was also a trend towards delays in symptom-to-FMC and in FMC-to-STEMI diagnosis.

These findings could be explained by increased COVID-19 cases, in British Columbia, including hospitalizations, within wave 3 compared to the prior waves. 21 Strict precautions to increase available healthcare resources and personnel were taken during wave 1, which were liberalized as the pandemic progressed. 24 These measures included reducing the number of elective cardiac and non-cardiac procedures to make facilities as well as health care personnel more available for the anticipated surge of COVID-19 cases. As there were less cases than expected in wave 1, and more than expected as the pandemic progressed when concurrently these precautions were liberalized, this led a relative mismatch in available resources and COVID-19 case surges. This increased stress on in-hospital systems from the surge in the COVID-19 pandemic, including the J o u r n a l P r e -p r o o f emergency department, may explain the delays in STEMI care including timely reperfusion.

We examined predictors of delayed FMC-to-device time. Consistent with prior pre-COVID-19 observations from our group, 25 we found that increasing age, cardiac arrest on presentation and presenting outside of daytime hours were associated with delays to reperfusion, and we did not identify any predictors of delays to reperfusion unique to the COVID-19 era.

Finally, within our exploratory in-hospital outcomes, we did not find a significant difference in hard clinical outcomes such as cardiac arrest, reinfarction, cardiogenic shock, or left ventricular function. Similarly, there was no difference in overall mortality or hospital length of stay. This trend of no difference in mortality despite increase in door-balloon time was also seen in previous observational studies. 10 

This is data that was collected from a single health authority. Although there are multiple referring centers within this health authority, our results are reflective of a single STEMI program and its inherent strengths and weaknesses. Similarly, despite our relatively large J o u r n a l P r e -p r o o f Canadian cohort, it is possible that we are underpowered to show statistically significant difference in clinical outcomes. Our results, however, are largely consistent with previously reported observational data from Canada as well as internationally, which suggests that our findings are largely generalizable. Furthermore, there was some missing data in our patient cohort, largely coming from the latest months of the COVID-19 pandemic. Overall, 3.9% of patients did not have complete demographic data and clinical data with respect to their STEMI presentation. However, with respect to the primary and secondary outcomes of interest, only 1.2% of patients did not have full data collected. As such, missing data was unlikely to affect the present findings.

The present study found delays in reperfusion during the COVID-19 pandemic compared to a historical control. Furthermore, delays in FMC to device time worsened over subsequent COVID-19 waves, coinciding with increased COVID-19 case burden in British Columbia. It is critical to further understand and adapt policy to address these care gaps during increased surges of COVID-19 cases to improve current gaps in STEMI care during these times. 

Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the Acute Management of ST-Elevation Myocardial Infarction: Focused Update on Regionalization and Reperfusion

Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China

ST-Segment-Elevation Myocardial Infarction during COVID-19 Pandemic: Insights from a Regional Public Service Healthcare Hub

Emergency Calling in COVID-19 Outbreak

Decrease in ST-segment elevation myocardial infarction admissions in Catalonia during the COVID-19 pandemic

Impact of COVID-19 outbreak on regional STEMI care in Germany

Impact of COVID-19-related public containment measures on the ST elevation myocardial infarction epidemic in Belgium: a nationwide, serial, cross-sectional study

Effect of the COVID-19 pandemic on mortality of patients with STEMI : a systematic review and meta--analysis

Evolution and Impact of a Regional Reperfusion System for ST-Elevation Myocardial Infarction

Association of Anemia with Outcomes Among ST-Segment-Elevation Myocardial Infarction Patients Receiving Primary Percutaneous Coronary Intervention

Predictors of the Use of Mineralocorticoid Receptor Antagonists in Patients with Left Ventricular Dysfunction Post-ST-Segment-Elevation Myocardial Infarction

Delays in ST-Elevation Myocardial Infarction Care During the COVID-19 Lockdown: An Observational Study

Early observations during COVID-19 pandemic in cardiac catheterization procedures for ST elevation myocardial infarctions (STEMI) across Ontario

Case rates, treatment approaches, and outcomes in acute myocardial infarction during the coronavirus disease 2019 pandemic

COVID-19: where have all the STEMIs gone?

Reduction in ST-segment cardiac catheterization laboratory activations in the united states during COVID-10 pandemic

Impact of COVID-19 outbreak and public lockdown on ST-elevation myocardial infaction care in Spain

The COVID-19 Pandemic and Coronary Angiography for ST-Elevation Myocardial Infarction, Use of Mechanical Support, and Mechanical Complications in Canada: A Canadian Association of Interventional Cardiology National Survey. CJC Open

British Columbia Center for Disease Control

Deaths due to delayed presentation to the hospital from fear of contracting COVID-19 during lockdown period: a tertiary care center experience

Where are all the COVID patients? Addressing COVID-19 Fear to Encourage Sick Patients to Seek Emergency Care

Precautions and Procedures for Coronary and Structural Cardiac Interventions During the COVID-19 Pandemic: Guidance from Canadian Association of Interventional Cardiology

Impact of Patient-and System-Level Delays on Reperfusion Among Patients With ST-Elevation Myocardial Infarction. CJC Open

We are indebted to the tireless work of the study coordinators who track down each case and enter data, the paramedics who managed each out of hospital cardiac arrest, the health care workers who provided post arrest care and to our patients who participate to advance our understanding of cardiac arrest and clinical outcomes.J o u r n a l P r e -p r o o f